Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals Inc (TARS) Implied Volatility Current
TARS implied volatility is 56%. IV Rank is 29%, placing current premiums in the bottom of their 52-week range.
Read more
Tracking TARS implied volatility helps you identify when options premiums on Tarsus Pharmaceuticals Inc are historically cheap or expensive, and where the best trades are hiding. Tarsus Pharmaceuticals Inc implied volatility reflects the market's expectation of future price movement: when TARS IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Tarsus Pharmaceuticals Inc's implied volatility current levels in real time and filter for high-probability trades.
Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For TARS, tracking metrics like TARS IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on TARS signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases.
Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where TARS implied volatility sits today versus where it has been. Our scanner ranks Tarsus Pharmaceuticals Inc implied volatility against its historical range, surfaces extremes in TARS IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Tarsus Pharmaceuticals Inc IV is rich or cheap — measure it, then act on it.
Implied Volatility
IV is below its typical range - premiums look reasonable for buyers.
As of September 18, 2026
Trade options with IV on your side
Track TARS IV rank across every expiration, spot where volatility is elevated, and identify high-probability setups before the window closes.
Start your 14-day free trial→